ct DNA (Circulating tumor DNA diagnosis on liquid biopsies)

GENDIA now offers Circulating Tumor DNA diagnosis on liquid biopsies (ct DNA) for lung cancer (Non-Small Cell Lung Cancer – NSCLC).

If tumor tissue is not available for analysis of oncogenic mutations, Circulating Tumor DNA diagnosis on liquid biopsies (ct DNA) is possible for some types of Cancer. Such testing analyses the Circulating Tumor DNA (ct DNA) released from cancer cells into the blood of the patient.

The essentials of the ct DNA test are summarized below, and more details can be found in our brochure.

Description

Currently Circulating tumor DNA diagnosis on liquid biopsies (ct DNA) is currently only offered for Non-Small Cell Lung Cancer (NSCLC), but it is expected that NIPD will become possible for many types of cancer in the near future.

ct DNA testing for Non-Small Cell Lung Cancer (NSCLC) detects the following mutations that confer sensitivity or resistance to tyrosine kinase inhibitors (TKIs):

  • EGFR: deletions in exon 19, L858R mutation in exon 2, T790M mutation in exon 20
  • KRAS: codon 12 and 13 mutations
  • BRAF: V600E, G469A and D594G mutations
  • ALK – EML4 fusion

Samples

Specific test kits provided by GENDIA are required: 20 ml blood in specific Streck blood tubes is required.

The samples have to be sent by Express mail to GENDIA’s lab in Antwerp (Belgium), and arrive there within 2 days of withdrawal.

Apart from ct DNA the same test can also be performed on FFPE material.

Turnaround Time

3 weeks.
Print Friendly, PDF & Email